Generic Annovera Availability
Last updated on Oct 7, 2026.
Annovera is a brand name of ethinyl estradiol/segesterone, approved by the FDA in the following formulation:
| Manufacturer | Approval date | Strengths [RLD] |
|---|---|---|
| MAYNE PHARMA | August 10, 2018 |
|
Has a generic version of Annovera been approved?
No, the FDA has not approved a generic version of Annovera.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Annovera. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Patent protection
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development. These patents may include claims related to the drug's formulation, manufacturing process, or other aspects.
| Patent Title | Method of providing birth control |
|---|---|
| Patent Number | 10,632,066 |
| Issue Date | April 28, 2020 |
| Inventor | Creasy & II George William & Merkatz Ruth Beverly |
| Current Assignee | The Population Council, Inc. |
| Patent Description |
The present disclosure describes a vaginal system comprising segesterone acetate and ethinyl estradiol configured for thirteen 28-day product-use cycles that is compatible with male condoms comprising natural rubber latex, polyisoprene, or...
The present disclosure describes a vaginal system comprising segesterone acetate and ethinyl estradiol configured for thirteen 28-day product-use cycles that is compatible with male condoms comprising natural rubber latex, polyisoprene, or polyurethane and a method of providing birth control using the vaginal system wherein a secondary contraception is employed when the vaginal system is removed or expelled from the vagina for specified amounts of time during any of the product-use cycles.
|
| Patent Expiry Dates |
|
| Patent Title | Method of providing birth control |
|---|---|
| Patent Number | 10,765,628 |
| Issue Date | September 8, 2020 |
| Inventor | Creasy & II George William & Merkatz Ruth Beverly |
| Current Assignee | The Population Council, Inc. |
| Patent Description |
The present disclosure describes a vaginal system comprising segesterone acetate and ethinyl estradiol configured for thirteen 28-day product-use cycles that is compatible with male condoms comprising natural rubber latex, polyisoprene, or...
The present disclosure describes a vaginal system comprising segesterone acetate and ethinyl estradiol configured for thirteen 28-day product-use cycles that is compatible with male condoms comprising natural rubber latex, polyisoprene, or polyurethane and a method of providing birth control using the vaginal system wherein a secondary contraception is employed when the vaginal system is removed or expelled from the vagina for specified amounts of time during any of the product-use cycles.
|
| Patent Expiry Dates |
|
| Patent Title | Method of providing birth control |
|---|---|
| Patent Number | 10,780,047 |
| Issue Date | September 22, 2020 |
| Inventor | Creasy & II George William & Merkatz Ruth Beverly |
| Current Assignee | The Population Council, Inc. |
| Patent Description |
The present disclosure describes a vaginal system comprising segesterone acetate and ethinyl estradiol configured for thirteen 28-day product-use cycles that is compatible with male condoms comprising natural rubber latex, polyisoprene, or...
The present disclosure describes a vaginal system comprising segesterone acetate and ethinyl estradiol configured for thirteen 28-day product-use cycles that is compatible with male condoms comprising natural rubber latex, polyisoprene, or polyurethane and a method of providing birth control using the vaginal system wherein a secondary contraception is employed when the vaginal system is removed or expelled from the vagina for specified amounts of time during any of the product-use cycles.
|
| Patent Expiry Dates |
|
| Patent Title | System for providing birth control |
|---|---|
| Patent Number | 10,918,649 |
| Issue Date | February 16, 2021 |
| Inventor | Variano; Bruce |
| Current Assignee | The Population Council, Inc. (New York, NY) |
| Patent Description |
The present disclosure relates to a vaginal system that prevents pregnancy comprised of segesterone acetate and ethinyl estradiol and is configured for thirteen 28-day product-use cycles.
|
| Patent Expiry Dates |
June 21, 2039
Drug Product: Yes |
| Patent Title | System for providing birth control |
|---|---|
| Patent Number | 10,925,882 |
| Issue Date | February 23, 2021 |
| Inventor | Variano Bruce |
| Current Assignee | The Population Council, Inc. |
| Patent Description |
The present disclosure relates to a vaginal system that prevents pregnancy comprised of segesterone acetate and ethinyl estradiol and is configured for thirteen 28-day product-use cycles.
|
| Patent Expiry Dates |
June 21, 2039
Drug Product: Yes |
| Patent Title | System for providing birth control |
|---|---|
| Patent Number | 10,940,157 |
| Issue Date | March 9, 2021 |
| Inventor | Variano; Bruce |
| Current Assignee | The Population Council, Inc. (New York, NY) |
| Patent Description |
The present disclosure relates to a vaginal system that prevents pregnancy comprised of segesterone acetate and ethinyl estradiol and is configured for thirteen 28-day product-use cycles.
|
| Patent Expiry Dates |
June 21, 2039
Drug Product: Yes |
| Patent Title | System for providing birth control |
|---|---|
| Patent Number | 11,529,308 |
| Issue Date | December 20, 2022 |
| Inventor | Variano; Bruce |
| Current Assignee | The Population Council, Inc. (New York, NY) |
| Patent Description |
The present disclosure relates to a vaginal system that prevents pregnancy comprised of segesterone acetate and ethinyl estradiol and is configured for thirteen 28-day product-use cycles.
|
| Patent Expiry Dates |
June 21, 2039
Drug Product: Yes |
| Patent Title | System for providing birth control |
|---|---|
| Patent Number | 11,850,251 |
| Issue Date | December 26, 2023 |
| Inventor | Variano; Bruce |
| Current Assignee | The Population Council, Inc. (New York, NY) |
| Patent Description |
The present disclosure relates to a vaginal system that prevents pregnancy comprised of segesterone acetate and ethinyl estradiol and is configured for thirteen 28-day product-use cycles.
|
| Patent Expiry Dates |
June 21, 2039
Patent Use: METHOD OF PREVENTING PREGNANCY BY INSERTING A VAGINAL SYSTEM CONTAINING 103 MG OF SEGESTERONE ACETATE AND 17.4 MG OF ETHINYL ESTRADIOL FOR UP TO 1THIRTEEN 21/7-DAY (IN/OUT) CYCLES |
| Patent Title | System for providing birth control |
|---|---|
| Patent Number | 12,303,518 |
| Issue Date | May 20, 2025 |
| Inventor | Variano; Bruce |
| Current Assignee | The Population Council, Inc. (New York, NY) |
| Patent Description |
The present disclosure relates to a vaginal system that prevents pregnancy comprised of segesterone acetate and ethinyl estradiol and is configured for thirteen 28-day product-use cycles.
|
| Patent Expiry Dates |
June 21, 2039
Drug Product: Yes |
More about Annovera (ethinyl estradiol / segesterone)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (104)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: contraceptives
- En español
Patient resources
Professional resources
Related treatment guides
Related/similar drugs
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.